An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined With KRT-232 in Patients With Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML)
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined With KRT-232 in Patients With Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML)
This study evaluates TL-895, a potent, orally available and highly selective irreversible tyrosine kinase inhibitor combined with navtemadlin (KRT-232), a novel oral small molecule inhibitor of MDM2 for the treatment of adults with FLT3 mutated Acute Myeloid Leukemia. Participants must be relapsed/refractory (e.g., having failed prior therapy) to be eligible for this study.
Inclusion Criteria:
Exclusion Criteria:
Chicago, Illinois 60612, United States
Philadelphia, Pennsylvania 19107, United States
Vienna, 1090, Austria
Halle, Saxony-Anhalt 06120, Germany
Essen, 45147, Germany
Hanover, 30625, Germany
Jena, 07747, Germany
Ancona, 60126, Italy
Meldola, 47014, Italy
Valencia, 46010, Spain